Financial Performance - For the first half of 2023, the company recorded revenue of RMB 47.6 million, a significant increase from RMB 1.0 million in the same period last year, representing a growth of approximately 4,660%[14]. - The company reported a gross profit of RMB 22.1 million for the first half of 2023, compared to RMB 691,000 in the same period of 2022[9]. - The pre-tax loss for the first half of 2023 was RMB 544.7 million, compared to a loss of RMB 463.5 million in the same period last year[9]. - The company recorded a revenue of RMB 476 million for the six months ended June 30, 2023, representing a significant increase of 4,442.3% compared to RMB 10.5 million for the same period in 2022[53]. - The net loss attributable to equity shareholders was RMB 539,012,000, compared to RMB 459,052,000 in the previous year, showing a worsening financial position[111]. - Total comprehensive loss for the period was RMB 541,530,000, compared to RMB 468,445,000 in 2022, indicating continued financial strain[112]. - The company reported a basic and diluted loss per share of RMB 0.56 for the period, compared to RMB 0.48 in the previous year, indicating a decline in earnings performance[111]. - The adjusted net loss for the six months ended June 30, 2023, was RMB 473.6 million, compared to RMB 400.7 million for the same period in 2022, reflecting an increase of approximately 18.2%[63]. Product Development and Commercialization - The core product, TUMAI, achieved four commercial installations during the reporting period and secured contracts in several top-tier hospitals in China[14]. - The company successfully generated overseas sales revenue for the first time with its product, HONGHU, through collaboration with MicroPort Medical Group[14]. - The flagship product, QINGTUIYAN, continued to show stable revenue growth, with both revenue and sales volume experiencing significant year-on-year increases[14]. - The new product, Mona Lisa, received NMPA approval in May 2023, becoming the first prostate puncture robot in the domestic market, filling a significant gap in medical options for patients[15]. - The company aims to enhance the surgical performance and product quality stability of its products, with a focus on meeting high-frequency surgical demands in commercialization[16]. - The company is focused on advancing its core strategy and achieving sustainable revenue growth through the commercialization of its existing products[14]. - The company plans to expand its product portfolio and establish a multi-specialty surgical robot platform to meet the growing demand for minimally invasive surgeries[50]. Market Expansion and Global Strategy - The company is actively advancing its global layout and resource integration, leveraging the extensive influence of the MicroPort Medical Group in the global medical device field[19]. - In the first half of 2023, the company's first overseas product, Honghu, generated sales revenue from international markets[19]. - The company has submitted a CE certification application for its flagship product, Tumai, as part of its overseas expansion plan[19]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share in the region by 2025[156]. - The company has received regulatory approval from ANVISA for its new surgical robot, facilitating entry into the Brazilian market[155]. Research and Development - The company continues to leverage its rapid R&D capabilities in China to meet clinical demands in the US market, facilitating quick iterations of its products[16]. - The company has applied for a total of 1,152 patents globally as of June 30, 2023, with 324 patents granted, including 230 in China and 94 overseas[48]. - Research and development expenses increased by 10% to RMB 200 million, focusing on advanced robotic systems and AI integration[154]. - The company is focused on five core underlying technologies for surgical robots, ensuring continuous product development and innovation[44]. Clinical Applications and Achievements - The company has completed over 1,200 robot-assisted clinical verification surgeries across more than 40 hospitals in 20 provinces, with over 700 surgeries completed this year alone, enhancing the technology and clinical application level[16]. - The 5G remote surgery initiative has successfully conducted nearly 50 surgeries, including the world's first 5G ultra-remote robotic liver resection and total hysterectomy surgeries, showcasing the company's advanced remote surgical capabilities[18]. - The company has established over 40 clinical application and training centers nationwide, providing comprehensive support services to empower grassroots medical institutions[16]. - The company has completed over 50 remote surgeries using 5G technology across various hospitals, setting multiple national and global records[43]. Financial Position and Liabilities - Total assets as of June 30, 2023, were RMB 1,744.0 million, down from RMB 1,930.1 million at the end of 2022[10]. - The company's total equity decreased to RMB 938.3 million as of June 30, 2023, from RMB 1,407.9 million at the end of 2022[10]. - Total interest-bearing borrowings increased significantly to RMB 459.2 million as of June 30, 2023, from RMB 33.1 million as of December 31, 2022[72]. - The net asset liability ratio increased to 48.9% as of June 30, 2023, compared to 2.4% as of December 31, 2022[72]. - Cash and cash equivalents decreased from RMB 748.0 million as of December 31, 2022, to RMB 704.6 million as of June 30, 2023, mainly due to increased marketing activities and ongoing R&D[68]. Corporate Governance and Compliance - The company aims to achieve a high level of corporate governance, which is crucial for development and safeguarding shareholder interests[100]. - The audit committee, consisting of three members, has reviewed and discussed the interim report for the six months ending June 30, 2023[102]. - The independent auditor's review of the interim financial report did not reveal any matters that would lead to a belief that the report was not prepared in accordance with the relevant standards[109]. - All directors and supervisors confirmed compliance with the standard code of conduct regarding securities transactions during the reporting period[91]. Shareholder Information - Major shareholder Shanghai Mo Hua holds 500,731,007 H shares, representing 52.60% of the class shares and 52.24% of the total shares[84]. - The company has a significant concentration of ownership, with major shareholders holding over 52% of the total shares[84]. - The share incentive plan allows for a maximum of 95,199,428 H shares to be awarded, representing approximately 9.93% of the company's issued share capital as of the report date[95].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上 海 微 創 醫 療 機 器 人（ 集 團 ）股 份 有 限 公 司 （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 截至2023年6月30日止六個月之 中期業績公告 董 事 會 欣 然 公 佈 本集 團 截 至 2023 年 6 月 30 日 止 六 個 月 之 未 經 審 核 綜 合 中期 業 績 ， 連 同 截 至 2022年6月30日止六個月之比較數字，已經審計委員會審閱。 於本公告內，「我們」及「我們的」指本公司及（ 倘文意另有所指 ）本集團。本公告所載若干金 額及百分比數據已因約整進行調整，或已約整至一個或兩個小數位。任何表格、圖表或其 他地方中總額與當中所列金額總和之間的任何差異乃因約整所致。 | --- | --- | --- | |---------------------- ...

Financial Performance - Total revenue for 2022 reached RMB 21,603,000, compared to RMB 2,150,000 in 2021, representing a significant increase[5] - Gross profit for 2022 was RMB 6,562,000, up from RMB 919,000 in 2021[5] - The company reported a pre-tax loss of RMB 1,146,284,000 for 2022, compared to a loss of RMB 584,507,000 in 2021[5] - The total equity decreased to RMB 1,407,878,000 in 2022 from RMB 2,390,152,000 in 2021[6] - The company recorded revenue of RMB 21.6 million, representing a 904.8% increase compared to RMB 2.2 million in the previous year[26] - The company recorded operating revenue of RMB 216 million for the year ended December 31, 2022, representing a growth of 904.8% compared to RMB 22 million for the year ended December 31, 2021, primarily due to rapid revenue growth from its flagship product, Dragonfly Eye[65] - Other net income for the year ended December 31, 2022, was RMB 421 million, compared to RMB 247 million for the year ended December 31, 2021, primarily from interest income and government subsidies[72] - The company recorded a net loss of RMB 27 million from financial instruments measured at fair value for the year ended December 31, 2022, compared to a net gain of RMB 455 million for the year ended December 31, 2021[73] - The adjusted net loss for the year ended December 31, 2022, was RMB 1,009.4 million, compared to RMB 452.8 million in 2021, reflecting an increase of 122%[77] Assets and Liabilities - Total assets decreased to RMB 1,930,125,000 in 2022 from RMB 2,791,884,000 in 2021[6] - Non-current assets increased to RMB 831,303,000 in 2022 from RMB 697,658,000 in 2021[6] - Cash and cash equivalents decreased from RMB 19,408 million as of December 31, 2021, to RMB 7,480 million as of December 31, 2022, primarily due to ongoing R&D and marketing activities[85] - The total interest-bearing borrowings as of December 31, 2022, were RMB 331 million, compared to zero as of December 31, 2021[89] - The net current asset value as of December 31, 2022, was RMB 7,735 million, down from RMB 18,598 million as of December 31, 2021, mainly due to continued expenditures in R&D, clinical registration, and commercialization activities[90] Product Development and Innovation - The company has developed multiple products across five major surgical specialties, including laparoscopic, orthopedic, and vascular surgery[8] - Three flagship products have received market approval through expedited channels[8] - The company aims to build a global medical robot innovation platform to enhance surgical capabilities[9] - The company is focusing on integrating new technologies such as artificial intelligence and 5G into its products to enhance their capabilities[22] - The company is committed to continuous R&D for the next generation of products, aiming to optimize the operational experience for surgeons and elevate Chinese laparoscopic technology to an international level[38] - The company is focused on the development of five core underlying technologies for surgical robots, ensuring continuous innovation and product development capabilities[52] Market Position and Strategy - The company is positioned as the only surgical robot company covering five major high-growth surgical specialties globally[11] - The global surgical robot market is projected to reach $28.51 billion by 2025, with a compound annual growth rate (CAGR) of 27.1% from 2021 to 2025[19] - The Chinese surgical robot market is expected to reach RMB 17.47 billion by 2025, with a CAGR of 42.9% from 2021 to 2025[19] - The company aims to continue exploring breakthroughs in surgical robot technology and its applications in remote surgery, enhancing healthcare quality in grassroots medical institutions[15] - The company plans to expand its product portfolio and establish a multi-specialty surgical robot platform to meet the growing demand for minimally invasive surgeries[60] - A global strategy is being pursued to build an innovative platform for medical robot solutions, integrating resources to enhance overseas commercialization and supply chain capabilities[62] Clinical Applications and Partnerships - The company established partnerships with nearly 100 hospitals, conducting around 2,000 clinical validations and doctor training surgeries, demonstrating the safety and effectiveness of its products[13] - Over 600 robot-assisted surgeries have been completed across nearly 30 hospitals in over ten provinces, demonstrating TUMAI's clinical application maturity and stability[34] - The company has established over 40 clinical application and training centers nationwide, enhancing the recognition and reputation of its innovative products[13] - The company has established over 30 clinical application and training centers nationwide for TUMAI, enhancing its recognition among hospitals and surgeons[33] Regulatory Approvals and Certifications - Tumai became the first four-arm laparoscopic surgical robot developed by a Chinese company to receive NMPA approval, while Honghu was the first domestic surgical robot to obtain NMPA, FDA, and CE certifications[14] - The Honghu product received certifications in China, the US, and Europe, successfully completing its first total knee replacement surgery in the US, laying a solid foundation for future overseas sales[12] - The "Honghu" orthopedic surgical robot received NMPA registration in April 2022 and obtained FDA 510(k) certification and EU CE certification in July and December 2022, respectively, becoming the first domestic surgical robot approved in China, the US, and the EU[40] Research and Development Expenses - Research and development costs rose by 92.5% to RMB 756 million for the year ended December 31, 2022, compared to RMB 393 million for the year ended December 31, 2021, driven by an increase in R&D personnel and related expenses[68] - The company reported R&D expenses of RMB 755.8 million for the fiscal year ending December 31, 2022, which significantly contributed to a major net loss[143] Management and Governance - The company emphasizes the importance of internal control and risk management through a supervisory board consisting of three members[114] - The company has expanded its management team with experienced professionals to strengthen its operational capabilities[122] - The company is actively involved in the development of new medical technologies and products, enhancing its market position[121] Shareholder Information - Major shareholders hold significant stakes in the company, with Shanghai Moku holding approximately 52.60% of H shares, translating to 500,731,007 shares[177] - The company has no distributable reserves as of December 31, 2022, consistent with the previous year[157] - The company maintains compliance with the relevant regulations regarding shareholdings and interests[175] Environmental Responsibility - The company is committed to environmental responsibility and integrates environmental factors into its operational strategies[138] - The company has a focus on creating environmentally sustainable business practices[138]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Shanghai MicroPort MedBot (Group) Co., Ltd. 上 海 微 創 醫 療 機 器 人（ 集 團 ）股 份 有 限 公 司 （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：2252） 截至2022年12月31日止年度 全年業績公告 董事會欣然公佈本集團截至2022年12月31日止年度經審核綜合業績，連同截至2021年12月 31日止年度之比較經審核數字。有關業績已經審計委員會審閱。 於本公告內，「我們」及「我們的」指本公司及（ 倘文意另有所指 ）本集團。本公告所載若干金 額及百分比數據已因約整進行調整，或已約整至一個或兩個小數位。任何表格、圖表或其 他地方中總額與當中所列金額總和之間的任何差異乃因約整所致。 | --- | --- | --- | |------------------------------------------------------- ...